【持續(xù)性腎臟替代治療crrt英文精品課件】liver failure_第1頁(yè)
【持續(xù)性腎臟替代治療crrt英文精品課件】liver failure_第2頁(yè)
【持續(xù)性腎臟替代治療crrt英文精品課件】liver failure_第3頁(yè)
【持續(xù)性腎臟替代治療crrt英文精品課件】liver failure_第4頁(yè)
【持續(xù)性腎臟替代治療crrt英文精品課件】liver failure_第5頁(yè)
已閱讀5頁(yè),還剩20頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Liverfailure Sub acuteliverfailureLowestriskofcerebraloedema encephalopathyEasilyconfusedwithCLDAscitesLowestchanceofspontaneoussurvival Hyper acuteliverfailureAcuteliverfailureGreatestriskofcerebraloedema CVSfailureGreatestchanceofspontaneoussurvival CauseAgentresponsibleViralHepatitisA B DE othersDrugrelatedIdiosyncraticanddoserelatedToxinsCarbontetrachloride PhosphorousAmanitaphalloidesVasculareventsIschemichepatitis Budd Chiari VOD heatshockliverOtherPregnancyrelated Wilsondisease lymphoma PrincipleCausesofAcuteLiverFailure NopreviousliverdiseaseVariousdefinitionsJaundiceorsymptomstoencephalopthy DecompensatedchronicliverdiseaseDecompensationwithsepsisBacterialperitonitis Rxas peritonitis Bacteraemia chest urineVaricealbleed frequentlyseptic endoscopicskills TIPSEncephalopathyHepatorenalfailureAlcoholichepatitis steroids pentoxifylline feed deltabilirubinDifferentialwithALF HistoryPatternofLFT sImaging ultrasound CTscanBiopsy varyrarelyindicatedLivertrauma Multisystemdisease CoagulopathyINRimportantprognosticindicatorinestablishedALFPlateletdysfunctionDIC rareMetabolicInsulinresistance ClarkeetalHepatologyHyperlactataemia BernaletalLancet2002 usefultotrackLivernetproduceroflactateMurphyetalCritCareMed2001P04 Mg Na glucose K pHHighincidenceofpancreatitisNutritionFrequentpoorrecentoralintake vomitingNoevidenceforproteinrestrictionineitheracuteorCLDGastricprophylaxisIncreasedmetabolicrequirementsWalshetalCCM2000 28 3 649 54 Renalfailure Common45 ofallcasesMultifactorial frequentlyprerenal ATNratherthanHRSRoleofintra abdominalpressureSpecificassociationswithviraldisease alcohol auto immuneCRRTorslowhaemodialysisisidealAnticoagulationepoprostenol heparin regionalanticoagulation citrate Infection ALF ImpairedinnateandcellularimmunityBacterialinfection335of887patients 550episodes Severesepsis58 mortalitySepticshock98 mortalityFungalinfection99of887 11 64 mortalityRolandoetalHepatology200032 734 31 4 872ComponentsofSIRSassociatedwithencephalopathyRolandoetalHepatology2000 32 734 9 VaqueroetalGastroenterology2003 125 755 64 ShawcrossDetalJHepatolinpressCultures Antibiotics broadinitially 5 7courseAntifungalsNobenefittoroutineprophylaxisorSelectivegutdecontaminationRolandoetalSeminLiverDis1996 16 389 402 RolandoetalLiverTransSurg1996 2 8 13 VasopressorsinALF Whatmeanarterialpressure Clinicalexamination invasiveDeterminedbyJVsaturationandICP autoregulatingornot Whichdrug DeterminefluidresponsivenessinitiallyWhateveryoucangetyourhandsonInsepsisandMOFepinephrinemaybedetrimentalincreasessplannchnicV02 glucoseturnoverMeierHellmanetal1997CritcareMedPhenylephrine decreasedflowwithdecreaseinsplV02ReineltCritCareMed1999 27 325NorepinephrineasfirstchoiceVasopressinmaybepotentiallydetrimental cerebralcomplicationsandpotentialsplanchnicischaemia ResultsstratifiedaccordingtobloodpressureondayofSST 0 500 1000 1500 NSP 0 01P 0 05 Baseline Increment Peak P 0 001 HarryetalHepatology2002 mortalityassociatedwithlowerbaselineandincrement p 0 05 correlateswithAPACHEIIIandSAPSNocorrelatewithotherparametersotherthancholesterol 57 ofpatientshaveabnormalsynacthenresponsehypotensionassociatedwithlowerbaselineandincrement p 0 05 Marik2005CCM53 1254LDLcholesteroldidseparategroups8 2 7 6vs28 4 14Mortality39 vs56 75 ofthoseonpressorshadabnormalresponse Encephalopathy HEofAcuteLiverFailureHepatocellularfailureRapidonsetCerebraloedemaMyoinositollevelsnotreducedCytotoxicandvasogenic PortalSystemicEncephalopathyPortalsystemicshuntspontaneouscollateralSurgicalTIPPSNotatriskofcerebraloedemaPrecipitatingfactorsSepsisSBPRxfluids AlbuminAvoidrenalfailureCNSactivedrugsElectrolyteabnormalitiesDiuretics overuseGastrointestinalbleeding HepaticencephalopathyinCLD Notacauseofdeath ProvidingtheairwayismanagedTreatprecipitatingcause sepsisscreen fluids AssociationofSIRSwithencephalopathyFeed stdprotein highcalorie fibrecontentideallyvegetablebasedLactuloseandenemas cleaningoracidificationAls NielsonBMJ2004 328 1064Non absorbableantibioticsDecreasingammoniatherapies i ornithineand ii benzoateBenzodiazepineantagonists noefficacyPomiers LayrarguesHepatology198910 969Sedation realriskinwardenvironmentYes theyareamenace upallnight climbingintothewrongbed shouting Progressiveneuropsychiatricsyndrome progressiveneuralinhibitionOccursinbothacuteandchronicliverdiseaseClinicalstatemaychangeveryrapidly IncidenceofcerebraloedemaReviewed229patientsGradeIII IVcoma1999 2002IncidenceHyperacute 24 Acute 23 Subacute 9 NH4NeurosteroidsInflammatoryresponse LarsenNeurochemInternational2004 44 ShawcrossLancet3652005 Increasedammoniaincerebraldeaths splanchnicammoniaproductionLarsenetalHepatology1998NH4cutoff124 pH cerebraloedema NH4predictoutcomeBhatiaVGut2005PartialpressureNH4correlateswithlevelofencephalopathyKramerHepatology2000 21CBFvariable lossofautoregulationtopressureTerlipressininALFShawcrossetal Hepatology2004 39 2 464 70 JalanetalGastroenterology2004 27 1338Cooledto32 33oC PREPOSTn 7ICP45 25 49 16 13 17 CBF103 25 134 44 24 75 CPP45 37 56 70 60 78 CI9 8 7 13 5 1 4 3 6 1 ArterialNH4343 109 490 to259 100 453 Uptake2 6 0 6 6 3 to 0 3 3 1 1 4 JalanetalLancet354 9185 11641999 N 14 ReductioninICPintreatmentgroup p 0 005 MurphyetalHepatology2004 39 2 464 70 Reducedriskofintracranialhypertension p 0 05 AgitationandairwaymanagementGradeIII IntubateventilateandsedatewithopiateandpropofolControlventilation avoidalkalosisPosition 10to20degreesheadupInsertreversejugularline JVsat55to80 Tightcontrolofglucose K pH Na 145 150mmol L MurphyetalHepatology2004 39 2 464 70Ammonia earlyCRRTMAP 65 frequentlynotautoregulating needtomeasureICPTreat ICP pupillaryabnormalitiesMannitol150ml20 osmolarity150 pressors fever hyperacuteandacute pupilllaryabnormalitiesTemperature avoidfever hypothermiashouldnotbeundertakenroutinely Currentlyavailable PhaseIIIstudywithBALDemetriouetalAnnSurg2004 239660 670 MARSTherapyMitzneretalLiverTranspl2000 6 277 286 HeemannetalHepatology2002 36 949 58 24patientswithCLDand acuteliverinjury MARSgroup reducedbileacids bilirubin encephalopathyControls biochemistrystatic worseningencephalopathyMARS11 12 SMT6 12 P 0 05 6mnthsurvival6 12MARSvs4 11 CoagulopathyandMARStreatmentinCLDDoriaetalClinicaltransplantation2004 18 365SinglePassAlbuminDialysis SPAD Clearanceofbilirubin bileacids NH4 improvedSauerHepatology2004 39 1048 MARSNathanetalLiverTransplant2004 10 1109LaiWetalIntCareMed2005 18patientswithalcoholrelatedAoCLDrandomizedtoMARSorSMTover7daysSignificantimprovementinencephalopathyNochangeinrenalfunctionorcreatinineNochangeinammoniaorcytokinelevels TNF IL 6 IL 10 IL 8 MDA MELDfellinbothgroups10patientswithALFgradeIII IVcomaTreated8hourson2consecutivedaysIncreaseSVRIonfirstRx1114 196to1432 245 changesnotsignificantbyendofsecondRxNochangeinICP14 5 7 25 to14 3 25 MARS SMTvs SMTAcuteonChronicLiverDiseasen 70SignificantimprovementsinencephalopathygradeNodifferencesinsurvivalHassaneinetalAASLD2004 OutcomeofCLDinITUWehleretalHepatology2001 34 255 261 143patients observationalstudy ApacheIII 90 pressors Clinicaljaundice 92 1monthMortalityvs11 inthosewith 3criteria420patientsGildeaChest2004 126 1598 30patientswithHRF8 3030daysurvival median21 Ventilatedsurvival0 15Non ventilatedsurvival8 15NodifferenceINR alb pressorsJGastroenterologyandHepatologyWitzkeetal200419 1369 AccuracyofICUscoringsystems ChildPugh0 72MELD0 72APACHEII0 78SOFA0 80 363patientswithCLDadmittedtoLITU PSE CVS RENALfailure 98 MortalitySOFAscorecutoff 13 Guidelinesforreferral ArterialpH3 0day2or 4 0thereafterINR 1 8oliguriaand

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論